Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | VCAM1 | P19320 | 7/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.41 |
| ▸ | MERTK | Q12866 | 2/20 | 0.40 |
| ▸ | GRM6 | O15303 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30583791 | 1.00 | TDP1 (0.60) | TDP1VCAM1TSHRMAPK1HTR2A | |
| SCHEMBL8313813 | 0.87 | VCAM1 (0.56) | TDP1VCAM1TSHRMAPK1MERTK | |
| SCHEMBL272708 | 0.85 | TDP1 (0.60) | TDP1VCAM1TSHRMAPK1MERTK | |
| SCHEMBL1115821 | 0.83 | TDP1 (0.62) | TDP1VCAM1TSHRMAPK1HTR2A | |
| SCHEMBL8390568 | 0.82 | VCAM1 (0.51) | TDP1VCAM1TSHRMAPK1MERTK | |
| SCHEMBL7860943 | 0.82 | VCAM1 (0.51) | TDP1VCAM1TSHRMAPK1RAB9A | |
| SCHEMBL2001345 | 0.82 | VCAM1 (0.51) | TDP1VCAM1TSHRMAPK1MERTK | |
| SCHEMBL1749233 | 0.82 | VCAM1 (0.47) | TDP1VCAM1TSHRMAPK1HTR2A | |
| SCHEMBL10989363 | 0.82 | VCAM1 (0.47) | TDP1VCAM1TSHRMAPK1HTR2A | |
| Hydroxyamine SCHEMBL6264479 | 0.81 | TDP1 (0.55) | TDP1VCAM1TSHRMAPK1MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113563579-B | Azobenzene-polyarylether nitrile composite material and preparation method thereof | 西南石油大学 | 2023-09-15 | — | — | CN | claimed |
| CN-113563579-A | Azobenzene-poly (arylene ether nitrile) composite material and preparation method thereof | 西南石油大学 | 2021-10-29 | — | — | CN | claimed |
| US-20260124209-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2026-05-07 | — | — | US | disclosed |
| US-12594276-B2 | Inhibitors of human immunodeficiency virus replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2026-04-07 | — | — | US | disclosed |
| EP-4225739-B1 | PREPARATION OF BENZIMIDAZOLONE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250249005-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2025-08-07 | — | — | US | disclosed |
| EP-4523755-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | F. Hoffmann-La Roche AG (CH) | 2025-03-19 | — | — | EP | disclosed |
| EP-3870577-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2025-03-19 | — | — | EP | disclosed |
| US-20250019383-A1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2025-01-16 | — | — | US | disclosed |
| CN-119039288-A | Pyrido [2,3-d ] pyrimidine derivatives as inhibitors of HIV replication | VIIV保健英国第五有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20240374598-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2024-11-14 | — | — | US | disclosed |
| US-6251903-B1 | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonist | COCENSYS, INC. | 2001-06-26 | — | — | US | disclosed |
| WO-2001025238-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
| WO-2001007912-A2 | IMMUNOASSAY FOR PESTICIDES AND THEIR DEGRADATION PRODUCTS | EXIQON A/S (US) | 2001-02-01 | — | — | WO | disclosed |
| US-6147075-A | ANALGESICS; PSYCHOLOGICAL DISORDERS | COCENSYS, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| EP-0732942-A4 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | COCENSYS INC (US) | 2000-03-22 | — | — | EP | disclosed |
| US-5977107-A | Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones and the use thereof as glycine receptor antagonists | COCENSYS, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5631373-A | NERVOUS SYSTEM DISORDERS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-05-20 | — | — | US | disclosed |
| EP-0732942-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995012417-A1 | ALKYL, AZIDO, ALKOXY, AND FLUORO-SUBSTITUTED AND FUSED QUINOXALINEDIONES AND THE USE THEREOF AS GLYCINE RECEPTOR ANTAGONISTS | ACEA PHARMACEUTICALS, INC. (US) | 1995-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594276-B2 | Inhibitors of human immunodeficiency virus replication | SAMHD1, IRF3, SLC34A1 | TDP1 3152/4885VCAM1 2437/4885TSHR 4820/4885 |
| US-20250019383-A1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | TYMP, TYMS, DPYD | TDP1 409/4885VCAM1 2505/4885TSHR 4461/4885 |
| US-20240374598-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, SAMHD1, POLR2H | TDP1 660/4885VCAM1 2710/4885TSHR 4804/4885 |
| US-20260124209-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | ZC3HAV1, GTF3C1, ODC1 | TDP1 1797/4885VCAM1 662/4885TSHR 2585/4885 |
| US-20250249005-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, REV1, RTF2 | TDP1 1161/4885VCAM1 1223/4885TSHR 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.